Lachen, Switzerland - (BUSINESS WIRE) - Octapharma CEO and Chairman Wolfgang Marguerre Commenting on the Group's results: "Octapharma in 2019 achieved particularly strong results we have achieved good growth in all three therapeutic areas. we continue to invest large sums of research and development, life-changing for the discovery and development of new therapies, and improve our plasma collection capacity, in order to ensure the future to provide patients with life-saving products. our new subcutaneous immunoglobulin (SCIG) cutaquig® in 2018 years to obtain approval in the United States and Canada, subsequently approved in Europe. the European medicines Agency (EMA) approved our recombinant factor VIII (rFVIII) Nuwiq® update the label to include the use of personalized preventive dose twice a week effective data protection bleeding. Fibryga® European approval for the treatment of acquired fibrinogen deficiency, compared to the earlier approved for congenital fibrinogen deficiency, therapeutic range has been expanded. these approvals bring to patients and physicians great benefits. based on our existing product portfolio and development pipeline, Octapharma is expected to The next few years continue to maintain a strong performance. "
Octapharma Group performed strongly in 2019. Sales revenue of 2.2 billion euros, an increase of 417 million euros (23.2%) compared with 2018. In addition, operating income in 2018 increased 78.6 million euros (22.7%) to 424 million euros.
2019 gross profit was 783 million euros, compared with 2018 increased 152 million euros. Although the Group continued to invest in plasma collection and production capacity to meet global demand for our products continues to grow, but the gross margin still rose from 0.3 to 35.4%.
For the future prosperity and development of the Group, the Group invest heavily in research and development and expansion of plasma collection and production capacity. Over the past 12 months, the Group achieved an important milestone in the expansion and application of plasma and recombinant product portfolio. In order to ensure full use per liter of plasma, the Group will continue to explore new markets and innovative products and services to the extended product portfolio.
Octapharma Group Chief Financial Officer Roger Mächler, said: " Last year, our products cover hundreds of thousands of patients worldwide, we invest heavily in research and infrastructure, strong support Octapharma in the coming years to meet the world more medical professionals and patients demand. "
2019 annual report provides a comprehensive overview of the Octapharma Group, including details of corporate governance and financial performance. To download Octapharma 2019 annual report, please visit: www.octapharma.com/annual-report .
About Octapharma
Octapharma Headquartered in Lachen, Switzerland, is the world's largest manufacturer of human proteins, committed to the development, production from human plasma and human cell lines of human proteins. As a family business, Octapharma is committed to effectively improve the quality of life, and since 1983 it has been the case; because it is our inherent mission.
In Octapharma, we drive our passion to provide new health solutions to improve human life. This is our vision. We organize flourish, employees have a sense of ownership, integrity, self-confidence to show practical leadership, promote sustainable development, and it may encourage the entrepreneurial spirit and a desire to embrace entrepreneurship.
We employ more than 9300 employees worldwide, with three main areas of products to support the treatment of 118 patients in the country are:
- Hematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Intensive Care (Treatment of bleeding and functional capacity supplement)
In addition to its more than 120 plasma centers in Europe and the United States outside, Octapharma also Austria, France, Germany, Mexico and Sweden have seven first-class R & D facilities and six manufacturing facilities
